A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.

NCT05878691 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

320

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Lymphoma

Interventions

DRUG: GRC 54276
DRUG: GRC 54276 + Pembrolizumab
DRUG: GRC 54276 + Atezolizumab

Sponsor

Glenmark Specialty S.A.